enue 7,092 5,327
Total current liabilities 46,045 61,543
Convertible debt 223,940 497,375
Long-term portion of acquisition obligation,
net of discount 68,548 66,553
Deferred revenue, net of current portion 5,023 --
Other long-term liabilities 2,078 2,082
Total liabilities 345,634 627,553
Stockholders' equity:
Common stock, $0.001 par value:
150,000,000 and 250,000,000 shares
authorized at December 31, 2006 and
December 31, 2007, respectively;
91,725,528 and 97,114,159 shares
issued and outstanding at December
31, 2006 and December 31, 2007,
respectively 92 97
Additional paid-in capital 709,359 794,917
Accumulated other comprehensive loss (25) 139
Accumulated deficit (591,624) (607,427)
Total stockholders' equity 117,802 187,726
Total liabilities and stockholders'
equity $463,436 $815,279
'/>"/>SOURCE BioMarin Pharmaceutical Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco2.
BioMarin to Present at the BioCentury NewsMakers Conference3.
BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference4.
BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease5.
BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture6.
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research7.
BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference8.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients9.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 2610.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering11.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.